Tagged with Biogen

Alzheimer’s: Is Lilly’s Donanemab Really a Game Changer?
Merck’s IRA Lawsuit Comes Under Fire from Own Shareholders
BIO2023: Biogen CEO Slams IRA and Talks M&A Opportunities
Alzheimer’s Immunotherapies: Are We There Yet?
Chirfi Guindo Comes Home to Merck after Biogen Parenthesis
Sergio Teixeira – Managing Director, Biogen Spain
Biosimilars: Should I Stay or Should I Go?
Five Leading Biosimilars Companies 2022
3 Regional Pharma Managers on their Middle East Go-To-Market Strategies
Ajai Sulekh – General Manager MART, Biogen
5 Denmark Pharma Country Managers Talk Market Access
Tashia Lentz – Managing Director, Biogen Denmark
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here